t
TheraCryf plc will release its final results for the year ended 31 March 2026 on Monday, 28 September 2026. A live presentation of these results will be given at 1:00 p.m. BST on the same date via Investor Meet Company by Dr Huw Jones, CEO, Toni Hänninen, CFO, and Dr Alastair Smith, Chair, open to existing and potential shareholders.
| Date | 14 Sept 2026 |
| Time | 07:00:11 |
| Category | Results |
| ID | 5093U |
14 September 2026
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Notice of Results and Investor Presentation
TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that the Company's final results for the year ended 31 March 2026 will be released on Monday, 28 September 2026.
A live presentation of the results will be given at 1.00 p.m. BST on Monday, 28 September 2026, via Investor Meet Company by Dr Huw Jones, Chief Executive Officer, Toni Hänninen, Chief Financial Officer and Dr Alastair Smith, Chair.
The results presentation will be open to all existing and potential shareholders. Questions can be submitted up to 24 hours prior to the event via the Investor Meet Company dashboard or during the live presentations.
Investors who already follow TheraCryf plc on the Investor Meet Company platform will automatically be invited. New registrants can sign up for Investor Meet Company HERE.
-Ends-
Enquiries
|
TheraCryf plc Dr Huw Jones, CEO Toni Hänninen, CFO Dr Helen Kuhlman, COO
|
+44 (0)1625 315 090 |
|
Singer Capital Markets (NOMAD & Joint Broker)
|
+44 (0)20 7496 3000 |
|
Turner Pope Investments (Joint Broker) Guy McDougall / Andy Thacker
|
+44 (0)20 3657 0050
|
|
Northstar Communications (Investor Relations) Sarah Hollins |
+44 (0)113 730 3896
|
About TheraCryf
TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need.
The Group's lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.
The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.
The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.
TheraCryf's headquarters and registered office are at Alderley Park, Cheshire.
For further information, visit: https://theracryf.com